Jci_page_head_homepage_01 Jci_page_head_homepage_02
Patrick C.H. Hsieh, Michael E. Davis, Joseph Gannon, Catherine MacGillivray, Richard T. Lee
Published in Volume 116, Issue 1
J Clin Invest. 2006; 116(1):237–248 doi:10.1172/JCI25878
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 3
Controlled local myocardial delivery of PDGF-BB using injectable self-assembling peptide NFs.

(A) PBS, BSA, PDGF-BB, VEGF-A, bFGF, or angiopoietin-1 (Ang-1) was embedded in NFs, and the binding capacity of NFs to individual protein was determined. (B) Rat left coronary artery was ligated to induce MI, followed with peptide NF injection in the border zones via 3 different directions. Myocardial protein was extracted from the injected areas, and retention of PDGF-BB, with or without NFs, was assessed using ELISA for human PDGF-BB. n = 6 for each group; no human PDGF-BB was detected in control animals with NFs alone (data not shown). **P < 0.001. (C) Immunohistochemistry of phospho–PDGFR-β (brown) in sections from different groups 14 days after MI. (D) Immunofluorescence staining of phospho–PDGFR-β in the myocardium after injection of NF/PDGF-BB. Shown is a 14-day section containing papillary muscle. Blue, DAPI; red, α-sarcomeric actinin; green, phospho–PDGFR-β. Scale bar: 5 μm. (E) Myocardial proteins were extracted 1 and 14 days after MI and subjected to Western blot analyses using antibodies against phospho–PDGFR-β, total PDGFR-β, phospho-Akt, and total Akt.